Literature DB >> 33925362

Hepatitis C Virus Uses Host Lipids to Its Own Advantage.

Malgorzata Sidorkiewicz1.   

Abstract

Lipids and lipoproteins constitute indispensable components for living not only for humans. In the case of hepatitis C virus (HCV), the option of using the products of our lipid metabolism is "to be, or not to be". On the other hand, HCV infection, which is the main cause of chronic hepatitis, cirrhosis and hepatocellular carcinoma, exerts a profound influence on lipid and lipoprotein metabolism of the host. The consequences of this alternation are frequently observed as hypolipidemia and hepatic steatosis in chronic hepatitis C (CHC) patients. The clinical relevance of these changes reflects the fact that lipids and lipoprotein play a crucial role in all steps of the life cycle of HCV. The virus circulates in the bloodstream as a highly lipidated lipo-viral particle (LVP) that defines HCV hepatotropism. Thus, strict relationships between lipids/lipoproteins and HCV are indispensable for the mechanism of viral entry into hepatocytes, viral replication, viral particles assembly and secretion. The purpose of this review is to summarize the tricks thanks to which HCV utilizes host lipid metabolism to its own advantage.

Entities:  

Keywords:  HCV; hypolipidemia; lipid droplets; lipoprotein receptors; lipoproteins; replication; steatosis; very low density lipoprotein assembly

Year:  2021        PMID: 33925362     DOI: 10.3390/metabo11050273

Source DB:  PubMed          Journal:  Metabolites        ISSN: 2218-1989


  121 in total

1.  Blood lipids of patients with chronic hepatitis: differences related to viral etiology.

Authors:  C Fabris; E Federico; G Soardo; E Falleti; M Pirisi
Journal:  Clin Chim Acta       Date:  1997-05-28       Impact factor: 3.786

2.  miR-122 and Ago interactions with the HCV genome alter the structure of the viral 5' terminus.

Authors:  Jasmin Chahal; Luca F R Gebert; Hin Hark Gan; Edna Camacho; Kristin C Gunsalus; Ian J MacRae; Selena M Sagan
Journal:  Nucleic Acids Res       Date:  2019-06-04       Impact factor: 16.971

3.  Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients.

Authors:  P Maillard; K Krawczynski; J Nitkiewicz; C Bronnert; M Sidorkiewicz; P Gounon; J Dubuisson; G Faure; R Crainic; A Budkowska
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

4.  Spatiotemporal Coupling of the Hepatitis C Virus Replication Cycle by Creating a Lipid Droplet- Proximal Membranous Replication Compartment.

Authors:  Ji-Young Lee; Mirko Cortese; Uta Haselmann; Keisuke Tabata; Inés Romero-Brey; Charlotta Funaya; Nicole L Schieber; Yu Qiang; Marie Bartenschlager; Stephanie Kallis; Christian Ritter; Karl Rohr; Yannick Schwab; Alessia Ruggieri; Ralf Bartenschlager
Journal:  Cell Rep       Date:  2019-06-18       Impact factor: 9.423

5.  Apolipoprotein E, but Not Apolipoprotein B, Is Essential for Efficient Cell-to-Cell Transmission of Hepatitis C Virus.

Authors:  Virgínia Gondar; Francisca Molina-Jiménez; Takayuki Hishiki; Luisa García-Buey; George Koutsoudakis; Kunitada Shimotohno; Ignacio Benedicto; Pedro L Majano
Journal:  J Virol       Date:  2015-07-22       Impact factor: 5.103

Review 6.  Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data.

Authors:  Francesco Negro; Arun J Sanyal
Journal:  Liver Int       Date:  2009-03       Impact factor: 5.828

7.  Hepatitis C virus RNA replication occurs on a detergent-resistant membrane that cofractionates with caveolin-2.

Authors:  Stephanie T Shi; Ki-Jeong Lee; Hideki Aizaki; Soon B Hwang; Michael M C Lai
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

8.  Hepatitis C virus proteins induce lipogenesis and defective triglyceride secretion in transgenic mice.

Authors:  Hervé Lerat; Hélène L Kammoun; Isabelle Hainault; Emilie Mérour; Martin R Higgs; Céline Callens; Stanley M Lemon; Fabienne Foufelle; Jean-Michel Pawlotsky
Journal:  J Biol Chem       Date:  2009-10-06       Impact factor: 5.157

9.  Metabolic disorders and steatosis in patients with chronic hepatitis C: metabolic strategies for antiviral treatments.

Authors:  Munechika Enjoji; Motoyuki Kohjima; Kazuhiro Kotoh; Makoto Nakamuta
Journal:  Int J Hepatol       Date:  2012-06-04

10.  Involvement of the 3' Untranslated Region in Encapsidation of the Hepatitis C Virus.

Authors:  Guoli Shi; Tomomi Ando; Ryosuke Suzuki; Mami Matsuda; Kenji Nakashima; Masahiko Ito; Tsutomu Omatsu; Mami Oba; Hideharu Ochiai; Takanobu Kato; Tetsuya Mizutani; Tatsuya Sawasaki; Takaji Wakita; Tetsuro Suzuki
Journal:  PLoS Pathog       Date:  2016-02-11       Impact factor: 6.823

View more
  6 in total

1.  Real-Life Early Anthropometric, Lipid and Liver Changes after Direct-Acting Antiviral Therapy in PLWHIV with HCV Co-Infection.

Authors:  Sergio Ferra-Murcia; Antonio Ramón Collado-Romacho; Bruno José Nievas-Soriano; Fernando Reche-Lorite; Tesifón Parrón-Carreño
Journal:  J Clin Med       Date:  2022-05-07       Impact factor: 4.964

2.  Are previous viral infections important on the COVID-19 outcomes?

Authors:  Jesus Torres-Flores; Nora A Fierro
Journal:  Ann Hepatol       Date:  2021 Nov-Dec       Impact factor: 2.400

3.  Serum Ceramide Species Are Associated with Liver Cirrhosis and Viral Genotype in Patients with Hepatitis C Infection.

Authors:  Marcus Höring; Georg Peschel; Jonathan Grimm; Sabrina Krautbauer; Martina Müller; Kilian Weigand; Gerhard Liebisch; Christa Buechler
Journal:  Int J Mol Sci       Date:  2022-08-29       Impact factor: 6.208

4.  A New Structural Model of Apolipoprotein B100 Based on Computational Modeling and Cross Linking.

Authors:  Kianoush Jeiran; Scott M Gordon; Denis O Sviridov; Angel M Aponte; Amanda Haymond; Grzegorz Piszczek; Diego Lucero; Edward B Neufeld; Iosif I Vaisman; Lance Liotta; Ancha Baranova; Alan T Remaley
Journal:  Int J Mol Sci       Date:  2022-09-29       Impact factor: 6.208

5.  Domain 2 of Hepatitis C Virus Protein NS5A Activates Glucokinase and Induces Lipogenesis in Hepatocytes.

Authors:  Laure Perrin-Cocon; Cindy Kundlacz; Clémence Jacquemin; Xavier Hanoulle; Anne Aublin-Gex; Marianne Figl; Jeremy Manteca; Patrice André; Pierre-Olivier Vidalain; Vincent Lotteau; Olivier Diaz
Journal:  Int J Mol Sci       Date:  2022-01-14       Impact factor: 5.923

Review 6.  PPAR Ligands Induce Antiviral Effects Targeting Perturbed Lipid Metabolism during SARS-CoV-2, HCV, and HCMV Infection.

Authors:  Marialuigia Fantacuzzi; Rosa Amoroso; Alessandra Ammazzalorso
Journal:  Biology (Basel)       Date:  2022-01-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.